Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.

Dorr, Anthony D; Chopra, Charu; Coulter, Tanya I; Dempster, John; Dziadzio, Magdalena; El-Shanawany, Tariq; Garcez, Tomaz; Gompels, Mark; Herriot, Richard; Jain, Rashmi; Levi, Marcel; Lorenzo, Lorena; Makki, Inas; Mapazire, Elizabeth; Murng, Sai H K; Noorani, Sadia; Savic, Sinisa; Steele, Cathal L; Symons, Christine; Tarzi, Michael; Yong, Patrick F K; Kiani-Alikhan, Sorena

Affiliation

Barts Health NHS Trust; Royal Infirmary of Edinburgh; Belfast Health and Social Care Trust; Sandwell and West Birmingham NHS Trust; et al.

Publication date

2022-12-21

Subject

Microbiology. Immunology

Metadata

Show full item record

Abstract

No abstract available.

Citation

Dorr AD, Chopra C, Coulter TI, Dempster J, Dziadzio M, El-Shanawany T, Garcez T, Gompels M, Herriot R, Jain R, Levi M, Lorenzo L, Makki I, Mapazire E, Murng SHK, Noorani S, Savic S, Steele CL, Symons C, Tarzi M, Yong PFK, Kiani-Alikhan S. Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit. Allergy. 2023 May;78(5):1369-1371. doi: 10.1111/all.15620

Type

Article